Evidence map›Paper›PMID 39449127›Full record

ArticlePneumonia (Nathan Qld.)2024

Clinical implications of persistently increased blood urea nitrogen/serum creatinine ratio (PI-BUN/Cr) in severe COVID-19 patients.

Gustavo Casas Aparicio, Rosario Fernández Plata, Anjarath Higuera Iglesias, David Martínez Briseño, Rolando Claure-Del Granado, Manuel Castillejos Lopez, Joel Vázquez Pérez, Noé Alvarado Vásquez, Rafael Velázquez Cruz, Graciela Hernández Silva and 12 more

Abstract read
In one paragraph

Article in Pneumonia (Nathan Qld.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Gustavo Casas Aparicio *Titular de la Coordination de Nefrología, Instituto Nacional de Enfermedades Respiratorias "Ismael Cosío Villegas", Calzada de Tlalpan 4502, Ciudad de México, 14080, México.
Rosario Fernández Plata *Unidad de Epidemiología Hospitalaria e Infectología, Instituto Nacional de Enfermedades Respiratorias "Ismael Cosío Villegas", Calzada de Tlalpan 4502, Col. Sección XVI, Ciudad de México, 14080, CP, México.
Anjarath Higuera Iglesias *Unidad de Epidemiología Hospitalaria e Infectología, Instituto Nacional de Enfermedades Respiratorias "Ismael Cosío Villegas", Calzada de Tlalpan 4502, Col. Sección XVI, Ciudad de México, 14080, CP, México.
David Martínez Briseño *Unidad de Epidemiología Hospitalaria e Infectología, Instituto Nacional de Enfermedades Respiratorias "Ismael Cosío Villegas", Calzada de Tlalpan 4502, Col. Sección XVI, Ciudad de México, 14080, CP, México. mb3david@gmail.com.
Rolando Claure-Del GranadoDivision de Nefrología, Cochabamba Bolivia and IIBISMED, Facultad de Medicina, Universidad Mayor de San Simón, Hospital Obrero No. 2 - CNS, Cochabamba, Bolivia.
Manuel Castillejos LopezUnidad de Epidemiología Hospitalaria e Infectología, Instituto Nacional de Enfermedades Respiratorias "Ismael Cosío Villegas", Calzada de Tlalpan 4502, Col. Sección XVI, Ciudad de México, 14080, CP, México. mcastillejos@gmail.com.
Joel Vázquez PérezLaboratorio de Biología Molecular de Enfermedades Emergentes y EPOC, Instituto Nacional de Enfermedades Respiratorias "Ismael Cosío Villegas", Calzada de Tlalpan 4502, Ciudad de México, 14080, México.
Noé Alvarado VásquezDepartmento de Investigación en Biomedicina Molecular e Investigación Translacional, Instituto Nacional de Enfermedades Respiratorias "Ismael Cosío Villegas", Calzada de Tlalpan 4502, Ciudad de México, 14080, México.
Rafael Velázquez CruzLaboratorio de Genómica del Metabolismo Óseo, Instituto Nacional de Medicina Genómica, Periferico Sur 4809, Ciudad de México, 14610, Mexico.
Graciela Hernández SilvaUnidad de Epidemiología Hospitalaria e Infectología, Instituto Nacional de Enfermedades Respiratorias "Ismael Cosío Villegas", Calzada de Tlalpan 4502, Col. Sección XVI, Ciudad de México, 14080, CP, México.
Victor RuizLaboratorio de Biología Molecular, Instituto Nacional de Enfermedades Respiratorias "Ismael Cosío Villegas", Calzada de Tlalpan 4502, Ciudad de México, 14080, México.
Ángel CamarenaLaboratorio de Inmunobiología y Genética, Instituto Nacional de Enfermedades Respiratorias "Ismael Cosío Villegas", Calzada de Tlalpan 4502, Ciudad de México, 14080, México.
Citlaltepetl Salinas LaraLaboratorio de Patología, Instituto Nacional de Neurología y Neurocirugía "Manuel Velazco Suarez", Insurgentes Sur 3877, Ciudad de México, 14269, México.
Martha Tena SuckLaboratorio de Patología, Instituto Nacional de Neurología y Neurocirugía "Manuel Velazco Suarez", Insurgentes Sur 3877, Ciudad de México, 14269, México.
Iñaki Montes de Oca AmbrizFacultad de Estudios Superiores Iztacala (Programa MEDICI), Universidad Nacional Autónoma de México, Av. de los Barrios 1, Tlalnepantla de Baz, Ciudad de México, 54090, México.
Oswaldo Ortiz ToledoFacultad de Estudios Superiores Iztacala (Programa MEDICI), Universidad Nacional Autónoma de México, Av. de los Barrios 1, Tlalnepantla de Baz, Ciudad de México, 54090, México.
Vianey Arvizu SerranoFacultad de Estudios Superiores Iztacala (Programa MEDICI), Universidad Nacional Autónoma de México, Av. de los Barrios 1, Tlalnepantla de Baz, Ciudad de México, 54090, México.
Yared Almazan ChaparroFacultad de Estudios Superiores Iztacala (Programa MEDICI), Universidad Nacional Autónoma de México, Av. de los Barrios 1, Tlalnepantla de Baz, Ciudad de México, 54090, México.
Edgar Flores-SotoDepartamento de Farmacología, Facultad de Medicina, Universidad Nacional Autónoma de México, Ciudad Universitaria, Ciudad de México, 04510, México.
Luz María Torres-Espíndola *Laboratorio de Farmacología, Instituto Nacional de Pediatría, Insurgentes Sur 3700, Ciudad de México, 04530, México.
Arnoldo Aquino-Gálvez *Titular de la Coordination de Nefrología, Instituto Nacional de Enfermedades Respiratorias "Ismael Cosío Villegas", Calzada de Tlalpan 4502, Ciudad de México, 14080, México.
Victor Hugo Ahumada Topete *Unidad de Epidemiología Hospitalaria e Infectología, Instituto Nacional de Enfermedades Respiratorias "Ismael Cosío Villegas", Calzada de Tlalpan 4502, Col. Sección XVI, Ciudad de México, 14080, CP, México.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPatients with COVID-19 may experience a persistent increase in the blood urea nitrogen over creatinine ratio (PI-BUN/Cr). Its elevation could reflect multiple underlying pathophysiological processes beyond prerenal injury but also warrants nuanced interpretation due to its complex interplay with various factors, underscoring the importance of investigating its effects on mortality and acute kidney injury in this population.

methodsWe analized a retrospective and longitudinal cohort of patients admitted to a single center in Mexico City for patients with severe COVID-19. Between March 5, 2020 and August 25, 2021, we included patients with confirmed positive diagnosis for SARS-CoV-2, age > 18 years, disease severity was defined by clinical data of respiratory distress syndrome and a ratio of partial oxygen pressure to inspired oxygen fraction < 300 mmHg on admission. We excluded patients with End Stage Kidney Disease. Data was obtained from electronic medical records. PI-BUN/Cr was defined as an increase in the BUN/Cr ratio > 30 in more than 60% of measurements in the hospital. The outcomes included: risk factors to mortality and AKI in-hospital.

resultsThe cohort included 3,007 patients with a median age of 54.6 ± 14.5 years. 35% of patients died; 44.6% developed PI-BUN/Cr ratio and 71.4% AKI. Mortality was associated with older age > 60 years [Hazard ratio (HR)] = 1.45, 95% CI: 1.28-1.65; p < 0.001); male (HR 1.25, 95% CI 1.09-1.44; p = 0.002) and AKI (HR 3.29, 95% CI 2.42-4.46; p < 0.001); PI-BUN/CR & Non-AKI (HR = 2.82, 95% CI: 1.61-4.93; p < 0.001); Non PI-BUN/CR & AKI (HR = 5.47, 95% CI: 3.54-8.44; p < 0.001); and PI-BUN/CR & AKI (HR = 4.26, 95% CI: 2.75-6.62, p < 0.001). Only hiperuricemia was a risk factor for AKI (HR = 1.71, 95% CI: 1.30-2.25, p < 0.001).

conclusionsWhile PI-BUN/Cr alone may not directly associate with mortality, its capacity to sub-phenotype patients according to their AKI status holds significant promise in offering valuable insights into patient prognosis and outcomes. Understanding the nuanced relationship between PI-BUN/Cr and AKI enhances our comprehension of renal function dynamics. It equips healthcare providers with a refined tool for risk stratification and personalized patient management strategies.

Indexed as

COVID-19PI-BUN/Cr and AKISub-phenotype

Identifiers

PMID39449127
PMCPMC11515407

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.